Table 2.
Multivariate Cox regression analysis of hallmark gene signatures after including sex, race, stage, grade and age.
| Tumor types | Sustaining proliferative signaling | Resisting cell death | Inducing angiogenesis | Genome instability | Evading growth suppressors | Enabling replicative immortality | Deregulation of cellular energetics | Activation invasion and metastasis | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| p | HR | p | HR | p | HR | p | HR | p | HR | p | HR | p | HR | p | HR | ||
| Bladder | 9.90E−09 | 0.78 | 1.45E−08 | 0.8 | 8.23E−09 | 1.48 | 1.92E−08 | 0.86 | 1.95E−08 | 0.86 | 5.56E−09 | 1.4 | 1.61E−08 | 1.17 | 6.76E−09 | 1.37 | |
| Breast | 1.05E−16 | 0.64 | 8.41E−17 | 0.69 | 3.23E−16 | 0.73 | 1.67E−16 | 1.57 | 1.59E−16 | 1.42 | 7.19E−18 | 1.88 | 1.93E−17 | 1.59 | 4.02E−16 | 1.34 | |
| Cervical | n.s | 0.82 | n.s | 1.08 | 4.85E−02 | 1.73 | 7.82E−05 | 0.32 | n.s | 1.25 | n.s | 1.3 | n.s | 0.81 | 1.14E−02 | 2.19 | |
| Colon | 1.45E−05 | 1.02 | 1.93E−06 | 0.55 | 1.31E−05 | 1.2 | 1.36E−05 | 0.97 | 1.29E−06 | 0.51 | 5.66E−06 | 1.57 | 1.40E−05 | 0.97 | 1.44E−05 | 1.01 | |
| Esophagus | 1.94E−02 | 0.84 | 1.73E−02 | 0.72 | 1.72E−02 | 0.77 | 1.77E−02 | 1.21 | 2.01E−02 | 0.93 | 9.40E−03 | 2.16 | 2.60E−04 | 3.68 | 1.80E−02 | 0.77 | |
| Glioblastoma | 1.38E−03 | 1.62 | 1.91E−03 | 1.53 | 7.66E−03 | 1.22 | 1.09E−03 | 0.64 | 2.44E−03 | 0.68 | 1.78E−03 | 1.51 | 8.59E−03 | 1.18 | 7.36E−03 | 1.26 | |
| Head and neck | 3.24E−05 | 0.81 | 5.94E−05 | 0.87 | 1.74E−05 | 1.34 | 2.89E−05 | 1.28 | 4.71E−05 | 0.85 | 4.79E−05 | 1.17 | 1.72E−06 | 1.83 | 6.61E−06 | 1.49 | |
| Kidney (clear cell) | 1.60E−24 | 0.85 | 1.77E−25 | 0.69 | 8.43E−25 | 0.86 | 1.08E−25 | 0.69 | 3.02E−25 | 0.73 | 1.25E−24 | 0.86 | 6.68E−26 | 0.67 | 6.87E−25 | 0.78 | |
| Kidney (papillary) | 4.69E−10 | 2.8 | 6.04E−10 | 2.76 | 5.53E−09 | 0.54 | 3.38E−09 | 2.04 | 3.08E−09 | 2.64 | 1.84E−09 | 2.29 | 5.41E−12 | 0.06 | 7.56E−09 | 1.49 | |
| AML | 8.22E−07 | 0.62 | 2.75E−06 | 0.76 | 4.57E−06 | 1.15 | 3.29E−06 | 1.28 | 1.44E−07 | 1.78 | 1.67E−06 | 1.41 | 6.19E−10 | 2.69 | 4.58E−08 | 1.98 | |
| Glioma | 5.29E−21 | 1.82 | 7.40E−19 | 0.91 | 5.72E−22 | 2.12 | 1.26E−20 | 1.7 | 2.49E−19 | 1.35 | 9.92E−24 | 2.28 | 9.58E−22 | 0.5 | 2.48E−24 | 2.67 | |
| Liver | 1.09E−05 | 1.57 | 2.40E−06 | 1.86 | 3.66E−05 | 0.7 | 1.01E−06 | 1.94 | 3.02E−05 | 1.37 | 2.89E−06 | 1.72 | 8.93E−05 | 1.09 | 1.12E−06 | 1.86 | |
| Lung (adeno) | 8.35E−08 | 1.36 | 1.35E−07 | 1.26 | 1.73E−07 | 0.84 | 1.22E−08 | 1.53 | 1.29E−07 | 1.31 | 4.11E−09 | 1.65 | 6.27E−08 | 1.53 | 5.86E−08 | 1.43 | |
| Lung (squamous) | 8.48E−07 | 1.99 | 9.11E−05 | 1.45 | 3.73E−04 | 1.34 | 1.54E−04 | 0.71 | 2.09E−04 | 0.71 | 1.09E−03 | 1.1 | 7.24E−04 | 0.83 | 2.79E−04 | 1.34 | |
| Ovarium | 1.68E−04 | 1.53 | 4.45E−03 | 0.87 | 1.05E−03 | 0.75 | 1.88E−03 | 0.77 | 5.94E−03 | 1.08 | 3.14E−03 | 0.83 | 4.26E−03 | 0.85 | 1.14E−03 | 1.36 | |
| Pancreas | 7.58E−03 | 2.03 | 3.70E−02 | 1.82 | n.s | 1.51 | 4.84E−02 | 1.52 | n.s | 1.37 | n.s | 1.42 | n.s | 1.32 | 1.53E−02 | 1.81 | |
| Paraganglioma | 6.27E−02 | 0.12 | n.s | 3.61 | n.s | 0.25 | n.s | 4.57 | n.s | 2.73 | n.s | 1.69 | n.s | * | n.s | 0.48 | |
| Prostate | n.s | * | n.s | inf | 9.98E−02 | * | n.s | inf | n.s | * | n.s | * | n.s | inf | n.s | * | |
| Rectum | 1.77E−02 | 2.8 | 1.36E−02 | 0.49 | 8.56E−03 | 0.44 | 2.90E−02 | 0.6 | 2.24E−02 | 0.64 | 3.54E−02 | 1.02 | 3.28E−02 | 1.39 | 3.53E−02 | 1.23 | |
| Sarcoma | 2.83E−02 | 1.51 | n.s | 0.73 | 2.47E−03 | 0.53 | 2.73E−03 | 2.01 | 2.40E−02 | 1.49 | 2.56E−02 | 1.47 | n.s | 1.18 | n.s | 0.71 | |
| Melanoma | 4.35E−10 | 0.67 | 4.29E−13 | 0.5 | 1.12E−10 | 0.61 | 8.21E−11 | 1.63 | 9.88E−09 | 1.1 | 2.58E−09 | 0.75 | 1.63E−10 | 1.6 | 9.99E−09 | 0.93 | |
| Stomach | 2.15E−03 | 1.14 | 2.20E−03 | 1.19 | 1.42E−03 | 1.35 | 1.28E−03 | 0.75 | 3.74E−04 | 0.64 | 1.67E−03 | 1.21 | 2.50E−03 | 0.92 | 1.00E−03 | 1.48 | |
| Testis | 5.88E−03 | * | 5.72E−03 | * | 3.58E−03 | * | 2.96E−03 | > 100 | 4.93E−03 | * | 5.81E−03 | * | 5.87E−03 | > 100 | 4.56E−03 | * | |
| Thyroid | 1.73E−10 | 0.4 | 6.54E−11 | 0.34 | 1.52E−11 | 3.38 | 2.36E−10 | 0.77 | 6.82E−11 | 2.02 | 6.40E−13 | 0.35 | 1.31E−11 | 6.24 | 2.29E−10 | 0.59 | |
| Thymoma | n.s | 0.43 | n.s | 2.35 | 1.24E−02 | 7.68 | 1.65E−02 | 0.08 | n.s | 0.25 | 8.35E−03 | 0.04 | 4.97E−02 | 4.11 | 2.83E−02 | 0.2 | |
| Uterine | 2.07E−07 | 1.56 | 9.32E−07 | 1.54 | 1.34E−06 | 0.85 | 1.58E−06 | 1.21 | 7.64E−07 | 1.43 | 1.01E−06 | 1.32 | 1.89E−06 | 1.02 | 1.62E−06 | 0.82 | |
Significant p (p < 0.05) and HR values in univariate and both uni- and multivariate survival analyses are bold and italics, respectively.
HR values with asterisk (*) shows that there are not any events in one of the groups in the survival analysis*.